On Aug. 10, 2020, Gilead Sciences announced that it had submitted a New Drug Application (NDA) to the FDA for Veklury (remdesivir), an investigational antiviral for the treatment of patients with COVID-19.

Veklury is currently available in the U.S. under an Emergency Use Authorization for the treatment of hospitalized patients with severe COVID-19. The filing is the final tier of the rolling NDA submission that was initiated on Apr. 8, 2020.